source
- Vertex to acquire Crinetics in $10 billion deal, expanding rare endocrine disorder pipelineVertex announced on July 7, 2026 that it will acquire Crinetics Pharmaceuticals for $10 billion, marking the company’s largest-ever transaction. Crinetics is a biotech focused on developing treatm…
- Vertex to acquire Crinetics in $10 billion deal, adding rare-disease drug Palsonify to its portfolioVertex Pharmaceuticals announced a $10 billion transaction to purchase Crinetics Pharmaceuticals. The deal will bring Crinetics' recently launched drug Palsonify into Vertex's portfolio. Palsonify…